Introduction/Aim. Pregnancy is one of the most important and enjoyable but often one of the most stressful periods in a woman's life. The most common fears that occur in this period of life are related to the health of the baby, the course of pregnancy, and childbirth. In order to get more information about the health status of a baby, there are a lot of prenatal diagnostic procedures which can be recommended to the pregnant women. Different studies have shown that in some healthcare systems health-care providers have gaps in knowledge in some areas of prenatal diagnostics and testing, primarily due to the constant advancement of prenatal diagnostic technology, introduction of new tests, and improvement of availability, specificity and sensitivity of the already existing prenatal tests. The aim of this paper was to systemize the current knowledge and provide medical professionals with new and detailed insight into the currently available methods of prenatal diagnostics, their informativeness, application, indications, contraindications, and possible complications in order to improve the current medical practice. Methods. Internet search engines were used to find and select relevant literature data. Conclusion. Constant monitoring of technology advancement, continuous education of health-care providers and publishing of new findings about currently available methods of prenatal diagnostics, represent necessary preconditions for improving the current medical practice and health of the patients.
References
1.
Amniocentesis: Indications and Risks. AMA Journal of Ethics. 10(5):304–6.
2.
Valente P, Sever JL. In utero diagnosis of congenital infections by direct fetal sampling. Isr J Med Sci. 1994;30(5–6):414–20.
3.
Oliveira FR, Barros EG, Magalhães JA. Biochemical profile of amniotic fluid for the assessment of fetal and renal development. Brazilian Journal of Medical and Biological Research. 2002;35(2):215–22.
4.
Cariati F, D’Argenio V, Tomaiuolo R. Innovative technologies for diagnosis and screening of genetic diseases in antenatal age. Journal of Laboratory and Precision Medicine. 5:6–6.
5.
Levy B, Wapner R. Prenatal diagnosis by chromosomal microarray analysis. Fertility and Sterility. 2018;109(2):201–12.
6.
StomornjakVukadin M, KurtovicBasic I, Mehinovic L, Konjhodzic R. Combined Use of Cytogenetic and Molecular Methods in Prenatal Diagnostics of Chromosomal Abnormalities. Acta Informatica Medica. 2015;23(2):68.
7.
Younesi S, Taheri Amin MM, Hantoushzadeh S, Saadati P, Jamali S, Modarressi MH, et al. Karyotype analysis of amniotic fluid cells and report of chromosomal abnormalities in 15,401 cases of Iranian women. Scientific Reports. 11(1).
8.
Tabor A, Alfirevic Z. Update on Procedure-Related Risks for Prenatal Diagnosis Techniques. Fetal Diagnosis and Therapy. 2010;27(1):1–7.
9.
Jindal A, Sharma M, Karena ZV, Chaudhary C. Amniocentesis. In: StatPearls Treasure Island. 2022.
10.
Jones TM, Montero FJ. Chorionic Villus Sampling. In: StatPearls Treasure Island (FL. 2022.
11.
ACOG Practice Bulletin No. 88: Invasive Prenatal Testing for Aneuploidy. Obstetrics & Gynecology. 2007;110(6):1459–67.
12.
Giovannopoulou E, Tsakiridis I, Mamopoulos A, Kalogiannidis I, Papoulidis I, Athanasiadis A, et al. Invasive Prenatal Diagnostic Testing for Aneuploidies in Singleton Pregnancies: A Comparative Review of Major Guidelines. Medicina. 58(10):1472.
13.
Wapner RJ. Invasive Prenatal Diagnostic Techniques. Seminars in Perinatology. 2005;29(6):401–4.
14.
Ota M, Fukushima H, Kulski JK, Inoko H. Single nucleotide polymorphism detection by polymerase chain reaction-restriction fragment length polymorphism. Nature Protocols. 2007;2(11):2857–64.
15.
Singh R, Hatt L, Ravn K, Vogel I, Petersen OB, Uldbjerg N, et al. Fetal Cells in Maternal Blood For Prenatal Diagnosis: A Love Story Rekindled. Biomarkers in Medicine. 2017;11(9):705–10.
16.
Chen Y, Wu Z, Sutlive J, Wu K, Mao L, Nie J, et al. Noninvasive prenatal diagnosis targeting fetal nucleated red blood cells. Journal of Nanobiotechnology. 20(1).
17.
Sabbatinelli G, Fantasia D, Palka C, Morizio E, Alfonsi M, Calabrese G. Isolation and Enrichment of Circulating Fetal Cells for NIPD: An Overview. Diagnostics. 11(12):2239.
18.
Tang Y, Tang Q, Luo H, Zhang X, Chen Q, Tang W, et al. Research Progress in Isolation and Enrichment of Fetal Cells from Maternal Blood. Journal of Chemistry. 2022;2022:1–8.
19.
Boulot P, Lefort G, Bachelard B, Humeau C. Cordocentesis versus amniocentesis for rapid fetal karyotyping in cases of late referral of women. J Perinat Med. 1992;20(2):159–61.
20.
Harper JC. Preimplantation genetic screening. Journal of Medical Screening. 2018;25(1):1–5.
21.
Coonen E, van Montfoort A, Carvalho F, Kokkali G, Moutou C, Rubio C, et al. ESHRE PGT Consortium data collection XVI–XVIII: cycles from 2013 to 2015†. Human Reproduction Open. 2020;2020(4).
22.
Leaver M, Wells D. Non-invasive preimplantation genetic testing (niPGT): the next revolution in reproductive genetics? Human Reproduction Update. 2020;26(1):16–42.
23.
Scriven PN, Handyside AH, Ogilvie CM. Chromosome translocations: segregation modes and strategies for preimplantation genetic diagnosis. Prenatal Diagnosis. 1998;18(13):1437–49.
24.
Wells D, Sherlock JK. Strategies for preimplantation genetic diagnosis of single gene disorders by DNA amplification. Prenatal Diagnosis. 1998;18(13):1389–401.
25.
Handyside AH, Kontogianni EH, Hardy K, Winston RML. Pregnancies from biopsied human preimplantation embryos sexed by Y-specific DNA amplification. Nature. 1990;344(6268):768–70.
26.
Kahraman S, Beyazyurek C, Tac HA, Pirkevi C, Cetinkaya M, Gulum N. Recent advances in preimplantation genetic diagnosis. Advances in Genomics and Genetics. :189.
27.
Lu L, Lv B, Huang K, Xue Z, Zhu X, Fan G. Recent advances in preimplantation genetic diagnosis and screening. Journal of Assisted Reproduction and Genetics. 2016;33(9):1129–34.
28.
Simpson JL, Lewis DE, Bischoff F, Elias S. La détection des cellules foetales dans le sangmaternal: vers un diagnostic prénatal non invasif [Detection of fetal cells in maternal blood: towards a noninvasive prenatal diagnosis. Contracept Fertil Sex. 1995;23(7–8):445–50.
29.
Peddi NC, Avanthika C, Vuppalapati S, Balasubramanian R, Kaur J, N CD. A Review of Cordocentesis: Percutaneous Umbilical Cord Blood Sampling. Cureus. 2021;
30.
Hsu WW, Hsieh CJ, Lee CN, Chen CL, Lin MW, Kang J, et al. Complication rates after chorionic villus sampling and midtrimester amniocentesis: A 7-year national registry study. Journal of the Formosan Medical Association. 2019;118(7):1107–13.
31.
Taylor TH, Gitlin SA, Patrick JL, Crain JL, Wilson JM, Griffin DK. The origin, mechanisms, incidence and clinical consequences of chromosomal mosaicism in humans. Human Reproduction Update. 2014;20(4):571–81.
32.
Malvestiti F, Agrati C, Grimi B, Pompilii E, Izzi C, Martinoni L, et al. Interpreting mosaicism in chorionic villi: results of a monocentric series of 1001 mosaics in chorionic villi with follow-up amniocentesis. Prenatal Diagnosis. 2015;35(11):1117–27.
33.
Shahbazian N, Barati M, Arian P, Saadati N. Comparison of complications of chorionic villus sampling and amniocentesis. Int J Fertil Steril. 2012;5(4):241–4.
34.
Bhatt RK. Chorionic Villus Sampling. Journal of Fetal Medicine. 2017;04(02):79–84.
35.
Wapner RJ. CHORIONIC VILLUS SAMPLING. Obstetrics and Gynecology Clinics of North America. 1997;24(1):83–110.
36.
Ghi T, Sotiriadis A, Calda P, Da Silva Costa F, Raine-Fenning N, Alfirevic Z, et al. ISUOG Practice Guidelines: invasive procedures for prenatal diagnosis. Ultrasound in Obstetrics & Gynecology. 2016;48(2):256–68.
37.
Dukhovny S, Norton ME. What are the goals of prenatal genetic testing? Seminars in Perinatology. 2018;42(5):270–4.
38.
Wapner RJ, Jenkins TM, Khalek N. Prenatal diagnosis of congenital disorders. 2004.
39.
Practice Bulletin No. 163. Obstetrics & Gynecology. 2016;127(5):e123–37.
40.
Practice Bulletin No. 162. Obstetrics & Gynecology. 2016;127(5):e108–22.
41.
Collins SL, Impey L. Prenatal diagnosis: Types and techniques. Early Human Development. 2012;88(1):3–8.
42.
Skirton H, Goldsmith L, Jackson L, Lewis C, Chitty L. Offering prenatal diagnostic tests: European guidelines for clinical practice. European Journal of Human Genetics. 2014;22(5):580–6.
43.
Liehr T, Lauten A, Schneider U, Schleussner E, Weise A. Noninvasive Prenatal Testing - When Is It Advantageous to Apply. Biomedicine Hub. 2(1):1–11.
44.
Lemacks J, Fowles K, Mateus A, Thomas K. Insights from Parents about Caring for a Child with Birth Defects. International Journal of Environmental Research and Public Health. 10(8):3465–82.
45.
Alliance G. The New York-Mid-Atlantic Consortium for Genetic and Newborn Screening Services. Understanding Genetics: A New York, Mid-Atlantic Guide for Patients and Health Professionals. 2009;
46.
Murugan VA, Murphy BO, Dupuis C, Goldstein A, Kim YH. Role of ultrasound in the evaluation of first-trimester pregnancies in the acute setting. Ultrasonography. 2020;39(2):178–89.
47.
Alliance G. The New York-Mid-Atlantic Consortium for Genetic and Newborn Screening Services. Understanding Genetics: A New York, Mid-Atlantic Guide for Patients and Health Professionals. 2009;
48.
Blakeley C, Smith DM, Johnstone ED, Wittkowski A. Parental decision-making following a prenatal diagnosis that is lethal, life-limiting, or has long term implications for the future child and family: a meta-synthesis of qualitative literature. BMC Medical Ethics. 2019;20(1).
49.
Bello O, Halifa I, Obajim G. Knowledge and attitude of healthcare providers towards prenatal screening and diagnosis in a lower-middle income country. TNHJ. 2022;22(3):244–9.
50.
Salehi A, Ahmad-Shirvani M, Mousavinasab N. Health-care providers’ knowledge about prenatal screening: A study in the north of Iran. Nurs Midwifery Stud. 2019;8:112–7.
51.
Levy B, Stosic M. Traditional Prenatal Diagnosis: Past to Present. Methods in Molecular Biology. 2019. p. 3–22.
52.
Kochanek KD, Kirmeyer SE, Martin JA, Strobino DM, Guyer B. Annual Summary of Vital Statistics: 2009. Pediatrics. 2012;129(2):338–48.
53.
Centers for Disease Control and Prevention (CDC). Update on overall prevalence of major birth defects--Atlanta, Georgia, 1978-2005. MMWR Morb Mortal Wkly Rep. 2008;57(1):1–5.
54.
Melender HL, Lauri S. Fears associated with pregnancy and childbirth — experiences of women who have recently given birth. Midwifery. 1999;15(3):177–82.
55.
Driscoll DA. Second trimester maternal serum screening for fetal open neural tube defects and aneuploidy. Genetics in Medicine. 2004;6(6):540–1.
56.
Okmen F, Ekici H, Hortu I, Imamoglu M, Arican D, Akın H, et al. Comparison of indications and results of prenatal invasive diagnostic tests before and after the implementation of the use of cell-free fetal DNA: a tertiary referral center experience. Journal of Assisted Reproduction and Genetics. 2020;37(8):2019–24.
57.
Shaw J, Scotchman E, Chandler N, Chitty LS. PREIMPLANTATION GENETIC TESTING: Non-invasive prenatal testing for aneuploidy, copy-number variants and single-gene disorders. Reproduction. 2020;160(5):A1–11.
58.
Swanson A, Sehnert AJ, Bhatt S. Non-invasive Prenatal Testing: Technologies, Clinical Assays and Implementation Strategies for Women’s Healthcare Practitioners. Current Genetic Medicine Reports. 2013;1(2):113–21.
59.
Lo YMD. Discovery of Cell-Free Fetal DNA in Maternal Blood and Development of Noninvasive Prenatal Testing. JAMA. 2022;328(13):1293.
60.
Rafi I, Chitty L. Cell-free fetal DNA and non-invasive prenatal diagnosis. British Journal of General Practice. 2009;59(562):e146–8.
61.
Álvarez-Nava F, Soto M, Padrón T. Maternal serum screening: clinical importance of falsepositive rate. Invest Clín [online. 2003;44(3):195–207.
62.
Boonpiam R, Wanapirak C, Sirichotiyakul S, Sekararithi R, Traisrisilp K, Tongsong T. Quad test for fetal aneuploidy screening as a predictor of small-for-gestational age fetuses: a population-based study. BMC Pregnancy and Childbirth. 2020;20(1).
63.
Graves JC, Miller KE, Sellers AD. Maternal serum triple analyte screening in pregnancy. Am Fam Physician. 2002;65(5):915–20.
64.
George A, Luz RF, De Tychey C, Thilly N, Spitz E. Anxiety symptoms and coping strategies in the perinatal period. BMC Pregnancy and Childbirth. 2013;13(1).
65.
Schiøtt KM, Christiansen M, Petersen OB, Sørensen TL, Uldbjerg N. The “Consecutive Combined Test”—using Double test from week 8 + 0 and Nuchal Translucency Scan, for first trimester screening for Down Syndrome. Prenatal Diagnosis. 2006;26(12):1105–9.
66.
Driscoll DA, Gross SJ. First trimester diagnosis and screening for fetal aneuploidy. Genetics in Medicine. 2008;10(1):73–5.
67.
<scp>ISUOG</scp> Practice Guidelines: performance of first‐trimester fetal ultrasound scan. Ultrasound in Obstetrics & Gynecology. 2013;41(1):102–13.
68.
Lee WA, Nelson G, Grogan SP. Sonography 1st trimester assessment, protocols, and interpretation.
69.
Getz L, Kirkengen AL. Ultrasound screening in pregnancy: advancing technology, soft markers for fetal chromosomal aberrations, and unacknowledged ethical dilemmas. Social Science & Medicine. 2003;56(10):2045–57.
70.
Leung KY, Poon CF, Teotico AR, Hata T, Won H, Chen M, et al. Recommendations on routine mid‐trimester anomaly scan. Journal of Obstetrics and Gynaecology Research. 2015;41(5):653–61.
71.
Whitworth M, Bricker L, Neilson JP, Dowswell T. Ultrasound for fetal assessment in early pregnancy. Cochrane Database of Systematic Reviews.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
